Apogee Therapeutics, INC Form 4 insider transactions

Fairmount Funds Management and associated directors plan to sell 1.75 million shares of Apogee Therapeutics common stock at $76.3 per share under a pre-arranged trading plan.

Apogee Therapeutics CEO Michael Henderson sold 19,000 shares of common stock on January 14, 2026, under a pre-arranged 10b5-1 trading plan.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and sold a portion of his common stock holdings under a pre-arranged trading plan, while also correcting a previous reporting error.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, was granted 83,690 stock options with an exercise price of $75.78.

Apogee Therapeutics CEO Michael Henderson was granted 253,016 stock options with a $75.78 exercise price, vesting over four years.

Apogee Therapeutics CFO Jane Henderson reported sales of 8,000 common shares and the grant of new stock options for 83,690 shares.

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 1,500 shares of common stock for $80 per share on December 19, 2025, as part of a Rule 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of common stock on December 10, 2025, under a Rule 10b5-1 trading plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold 10,900 shares of common stock for approximately $75 per share as part of a pre-arranged trading plan.

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 1,500 shares of common stock for $75 per share, executed under a pre-arranged 10b5-1 trading plan.

Apogee Therapeutics' CEO, Michael Henderson, sold 40,000 shares of common stock for approximately $75.01 per share under a pre-arranged trading plan.

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 1,500 shares of common stock for $70 per share on November 25, 2025, as part of a pre-arranged trading plan.

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 2,000 shares of common stock for $65 per share, as part of a pre-arranged 10b5-1 trading plan.

Apogee Therapeutics CFO Jane Henderson sold 1,000 shares of common stock for $60 per share, executed under a pre-arranged 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson sold 19,990 shares of common stock on November 13, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and subsequently sold common stock under a pre-arranged 10b5-1 trading plan.

Apogee Therapeutics director Nimish Shah reported the indirect acquisition of 365,853 pre-funded warrants through Venrock Opportunities Fund, L.P., signaling confidence in the company's future.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, executed a pre-arranged trading plan, exercising stock options and subsequently selling common stock.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 2,725 shares of common stock in pre-planned transactions.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 2,725 shares of common stock for $37.78 per share under a Rule 10b5-1 trading plan.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and subsequently sold a portion of his common stock holdings on July 2, 2025, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics, Inc. directors Peter Harwin and Tomas Kiselak, associated with Fairmount Funds Management LLC, were granted stock options to purchase 14,461 shares each, with an exercise price of $41.66, set to vest on June 17, 2026.

Apogee Therapeutics, Inc. Director Nimish P. Shah was granted 14,461 stock options with an exercise price of $41.66, vesting one year from the grant date of June 17, 2025.

Apogee Therapeutics, Inc. Director Mark C. McKenna was granted 14,461 stock options with an exercise price of $41.66, vesting on the one-year anniversary of the grant date.

Apogee Therapeutics, Inc. director William A. Jones Jr. was granted stock options to purchase 14,461 shares of common stock at an exercise price of $41.66 per share, vesting one year from the grant date.

Apogee Therapeutics, Inc. Director Andrew Gottesdiener was granted 14,461 stock options with an exercise price of $41.66, vesting on the one-year anniversary of the grant date.

Apogee Therapeutics, Inc. Director Jennifer A. Fox was granted 14,461 stock options with an exercise price of $41.66, vesting over one year.

Apogee Therapeutics, Inc. Director Lisa Bollinger was granted stock options to purchase 14,461 shares of common stock at an exercise price of $41.66, vesting one year from the grant date.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 2,725 shares of common stock for approximately $100,734, executed under a Rule 10b5-1 trading plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold 2,725 shares of common stock at an average price of $35.75, according to a Form 4 filing with the SEC.